Ydreborg S O, Svedmyr N, Thiringer G
Scand J Respir Dis. 1977 Apr;58(2):117-24.
In a double-blind long-term study, regular inhalations of a short-acting selective beta2-stimulator, rimiterol, was compared with a long-acting one, terbutaline. The trial comprised 60 patients with chronic obstructive lung disease, all patients were on a small dose of an oral beta2-stimulator. Both drugs were regularly given in aerosol form with a minimum dose of three inhalations three times daily. The main purpose was to study subjective and objective side effects. Haematological, hepatic and renal functions were screened for toxicity. Consumption of spray was recorded. No side effects occurred. There was no evidence of development of isoprenaline resistance. The consumption of spray was the same in both groups. In this study, regular inhalation treatment of rimiterol seemed to be as effective as terbutaline in long-term bronchodilator therapy.
在一项双盲长期研究中，将短效选择性β2激动剂利米特罗的常规吸入与长效β2激动剂特布他林进行了比较。该试验纳入了60例慢性阻塞性肺疾病患者，所有患者均服用小剂量口服β2激动剂。两种药物均以气雾剂形式定期给药，最低剂量为每日三次，每次至少吸入三次。主要目的是研究主观和客观副作用。对血液学、肝脏和肾脏功能进行毒性筛查。记录喷雾剂的消耗量。未出现副作用。没有证据表明出现异丙肾上腺素耐药性。两组的喷雾剂消耗量相同。在本研究中，利米特罗的常规吸入治疗在长期支气管扩张剂治疗中似乎与特布他林一样有效。
